NASDAQ · Biotechnology

ARTL (ARTL) Stock

$0.77 +1.96% NASDAQ: ARTL Healthcare

Valuation

MetricValue
Price$0.77
Market Cap$1.80M
P/E Ratio-0.12
P/B Ratio0.12
P/S Ratio0.00
EPS (TTM)$0.00
52-Week High$85.80
52-Week Low$0.77
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE1300.00%
ROA-107.57%
ROCE-175.10%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.11
Current Ratio0.25

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-7.0M$-10.0M$-10.0M$-10.0M$-11.0M
Net Profit$-7.0M$-10.0M$-9.0M$-10.0M$-13.0M
EPS$-1.99$-1.16$-1.05$-1.02$-5.47
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$13.0M$20.0M$13.0M$5.0M$3.0M
Total Liabilities$1.0M$1.0M$1.0M$2.0M$4.0M
Cash$7.0M$7.0M$3.0M$2.0M$1.0M
Borrowings$0$0$0$0$1.0M

Latest News

Artelo Biosciences Announces New Data Supporting ART26.12 as a Potential First-in-Class Therapy for Chronic Pain associated with Spinal Cord Injury GlobeNewswire · Jul 1, 2026 Artelo Biosciences Presents Evidence for a Common Lipid-Signaling Link Across Multiple Potential Indications for Its FABP5 Inhibitor Platform at ICRS 2026 GlobeNewswire · Jun 30, 2026 Artelo Biosciences Presents Clinical and Biomarker Data Supportive of the Development of ART26.12 and Follow-On FABP5 Inhibitors at ICRS 2026 GlobeNewswire · Jun 29, 2026 Artelo Biosciences Presents ART26.12 Human Metabolite Data Demonstrating Favorable Drug Metabolism Characteristics Associated with Clinical Development Success GlobeNewswire · Jun 10, 2026 Top Premarket Decliners MT Newswires · May 27, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-6.0M$-8.0M$-8.0M$-8.0M$-9.0M
Investing Cash Flow$-1.0M$3.0M$4.0M$8.0M$0
Financing Cash Flow$6.0M$0$0$0$0
Net Cash Flow$4.0M$-5.0M$-4.0M$0$-2.0M
Free Cash Flow$-6.0M$-8.0M$-8.0M$-8.0M$-9.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA0.55
FCF Yield-313.23%
Quick Ratio1.79
Interest Coverage-17.13
Return 1Y-97.61%
Return 3Y-96.77%
Return 5Y-99.57%

Ownership

Insiders Held2.47%
Institutions Held8.10%
Institutions Float Held8.31%
Institutional HolderSharesReport Date
Kathmere Capital Management, Llc13,2502026-03-31
Jane Street Group, LLC13,0792026-03-31
Vanguard Capital Management LLC10,1292026-03-31
Vanguard Fiduciary Trust Co3,1392026-03-31
Citigroup Inc.3,0762026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
CARMCarisma Therapeutics, Inc. $0.01 -5.17% 0.01 $230148 0.00%
GTBP $0.29 -4.65% -0.07 $3.12M 0.00%
LIPOLipella Pharmaceuticals Inc. $0.07 +0.00% -0.05 $300354 0.00%
PBM $3.30 +4.76% 2.76 $62763 0.00%
PTIXProtagenic Therapeutics, Inc. $0.26 +18.18% -0.08 $470654 0.00%

About ARTL

ARTL is led by CEO Gregory D. Gorgas, publicly traded since 2019.

ARTL stock trades at $0.77 with a market capitalization of $1.80M. The stock is valued at a price-to-earnings (P/E) ratio of -0.12, price-to-book of 0.12, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.77 and $85.80, and currently trades 99.1% below its 52-week high.

On profitability, ARTL generates a return on equity (ROE) of 1300.00% — well above the market average, a sign of a high-quality business, return on capital employed of -175.10%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides